Nuvaring (Ethinylestradiol, Etonogestrel)

Etonogestrel/ethinyl estradiol, the active ingredient in NuvaRing, is a combined estrogen‑progestogen contraceptive presented as a vaginal ring releasing 0.015 mg/day ethinyl estradiol and 0.12 mg/day etonogestrel for vaginal use. It is indicated for prevention of pregnancy in women of reproductive age.

GNH USA supplies NuvaRing as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

NuvaRing, a combined estrogen‑progestogen contraceptive, is used within the hormonal contraception pathway to prevent unintended pregnancy.

- Prevention of pregnancy: provides reliable, reversible contraception for women of childbearing potential. - Family planning: enables controlled spacing of pregnancies when used as directed. - Contraceptive management: offers a user‑controlled, monthly method that does not require daily dosing.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Breast tenderness: transient discomfort in the breasts. - Headache: occasional tension‑type headaches. - Mood changes: irritability or emotional fluctuations. - Vaginal irritation: local itching or discharge. - Spotting: irregular bleeding between cycles.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins. - Pulmonary embolism: clot migration to the lungs. - Stroke: cerebrovascular accident due to clot or hemorrhage. - Myocardial infarction: heart attack risk in susceptible individuals. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Liver dysfunction: abnormal liver enzymes or jaundice.

Before using NuvaRing, consider the following precautions.

- Smoking: avoid if over 35 years of age and a smoker, due to increased thrombotic risk. - History of thromboembolism: contraindicated in patients with prior deep vein thrombosis or pulmonary embolism. - Liver disease: use with caution in moderate to severe hepatic impairment. - Hypertension: monitor blood pressure regularly during use. - Breast cancer: contraindicated in current or past breast cancer patients. - Store at ambient temperature: keep in original packaging, protect from moisture and excessive heat.

NuvaRing may interact with other medicines; review the following.

Major Interactions (Avoid): - Enzyme inducers (e.g., rifampin, phenytoin, carbamazepine): reduce contraceptive effectiveness. - Certain antiretrovirals (e.g., efavirenz): may lower hormone levels. - St. John’s wort: herbal inducer that can diminish efficacy. - Some antibiotics (e.g., rifampin): may increase hormone metabolism. - Anticonvulsants (e.g., phenobarbital): can decrease contraceptive reliability.

Moderate Interactions (Monitor Closely): - Other hormonal therapies (e.g., hormone replacement): may alter overall hormone exposure. - Antifungals (e.g., ketoconazole): can increase hormone concentrations. - SSRIs (e.g., fluoxetine): may affect bleeding patterns. - Diuretics (e.g., thiazides): may influence fluid balance and blood pressure. - Herbal supplements (e.g., ginseng): potential modest effect on hormone levels.